U.S. judge denies effort to block Eli Lilly's weight-loss ad; GSK reports oncology drug approval
A U.S. district judge rejected a request to halt Eli Lilly's advertising campaign that Novo Nordisk alleges is deceptive in promoting its weight‑loss medicines.
Novo Nordisk argued the ads could mislead patients about the efficacy and safety of the drugs, but the court found no sufficient basis to issue an injunction.
In separate news, GlaxoSmithKline announced that one of its cancer therapies received regulatory approval for an additional tumor indication, marking a continued expansion of its oncology portfolio.
Both developments underscore ongoing regulatory scrutiny in drug marketing and the importance of new approvals for pharma growth strategies.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that